Skip to content

PRO*MDD: Effectiveness of outpatient treatment PROgrams for Major Depressive Disorder: Metacognitive Therapy vs. Behavioral Activation

PRO*MDD: Effectiveness of outpatient treatment PROgrams for Major Depressive Disorder: Metacognitive Therapy vs. Behavioral Activation

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00011536
Enrollment
128
Registered
2017-02-13
Start date
2016-09-27
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F33 F32

Interventions

Group 1: outpatient Metacognitive therapy -programm (MCT) with one individual and one group session per week for 6 months Group 2: outpatient Behavioral Activation-programm (BA) with one individual a

Sponsors

Klinik für Psychiatrie und Psychotherapie, Universität zu Lübeck
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Primary Diagnosis of MDD according to DSM-IV (SCID-I-Interview) severity of depression > 16 Punkte in HRSD-Interview. willingness to participate in the study (informed consent) willingness to participate over a maximum of 6 months in the study and take part in the therapy session regularly (no plans to move or to have inpatient treatment)

Exclusion criteria

Exclusion criteria: lifetime diagnosis of psychotic disorder lifetime diagnosis of bipolar disorder IQ below 85 acute sucidality acute serious substance abuse disorder, that calls for detoxication Inadequate german language skills

Design outcomes

Primary

MeasureTime frame
primary outcome: severity of depressive symptoms assessed by the Hamilton Rating Scale for Depression (HRSD) at the end of treatment (6 months assessment)

Secondary

MeasureTime frame
Secondary outcomes address general psychopathology (BSI), quality of life (SF-12), psychosocial functioning and participation (WHODAS), course of other psychiatric disorders (SKID I und II), metacognitions, rumination and worying (MDD-S, MCQ-30, RSQ-D) as well as behavioral activation (BADS).Secondary Outcomes will be assessed at baseline as well as 3, 6, 12, 18 and 30months after start of treatment

Countries

Germany

Contacts

Public ContactEva Faßbinder

Klinik für Psychiatrie und Psychotherapie, Universität zu Lübeck

eva.fassbinder@uksh.de0451-50098702

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 23, 2026